Aurobindo Pharma's Curateq gets Health Canada NOC for Bevqolva Biosimilar
Aurobindo Pharma's wholly-owned subsidiary, CuraTeQ Biologics Private Limited, has received a Notice of Compliance (NOC) from Health Canada for its bevacizumab biosimilar, Bevqolva™. This approval grants formal marketing authorization, confirming the biosimilar meets regulatory standards for safety, efficacy, and quality, comparable to the reference biologic drug Avastin. Bevacizumab is a humanized monoclonal antibody used to treat various cancers, including colorectal and lung, by inhibiting new blood vessel formation. Bevqolva™ was commercially launched in the UK in 2025 and is currently under review by the European Medicines Agency. CuraTeQ Biologics also has two additional biosimilar applications under review by Health Canada. This marks a significant regulatory milestone for Aurobindo Pharma, expanding its biosimilar presence in key international markets.
Key Highlights
- Aurobindo Pharma's subsidiary secured Health Canada NOC for Bevqolva biosimilar.
- This approval enables marketing authorization for Bevqolva in Canada.
- Bevqolva targets multiple cancers, including colorectal and lung.
- The product is already launched in the UK and under EU review.
- Two more biosimilar applications are under Health Canada review.
Price Impact